The $541,000 Insider Sale Is Noise. Chemed's $16 Million Cap-Swing Beat Is the Signal.

On August 21, an executive sold 1,000 shares of Chemed for $541,040, and the financial wires filed it as news. Form 4, after all, is where investors look for the people who know a company best stepping toward or away from the exit. The filing itself is real enough. The question is whether it says anything worth knowing.

Spencer S. Lee, Chemed's executive vice president and the chairman and CEO of its Roto-Rooter arm, sold those shares at $541.04 and was left holding 13,912 shares. Now weigh the scale. Chemed is a roughly $6.8 billion company with about 13 million shares on issue. The sale amounts to a rounding error: about 0.008 percent of the company. The stake he kept is worth around $7 million.

Everything else about the trade reads as routine rather than ominous. Lee is 70, has spent his career at Chemed since 1980, and has been trimming roughly a thousand shares a year — a similar sale in November 2023, 1,016 shares in August 2024, now 1,000 more in August 2026. That is what a longtime executive in his seventies does with concentrated compensation: it is diversification, not a change of conviction. There is no corroborating signal — no cluster of officers selling, no CFO, no audit-committee exit, nothing that would move this up an evidence ladder.

The most telling comparison, though, points the other way. One quarter before Lee's sale, Chemed itself repurchased 500,000 of its own shares — five hundred times the 1,000 he sold — for $197.7 million at an average price near $395. The people who run the company committed close to $200 million buying in; the headline services wrote an alert about one insider selling a fraction of a percent out. Whatever direction the company's own money points is fairly clear, and it is not toward the door.

So the sale resolves to noise. But it is a useful door, because it leads to the number worth interrogating: the quarter that fired the stock.

The beat that came partly from a reserve

Chemed has traded around $520 after a roughly 30 percent run over four months, within reach of its 52-week high near $557 and up more than 20 percent this year. On trailing earnings it carries a price-to-earnings multiple near 25 and an enterprise value about 16.6 times EBITDA. A stock that runs that far that fast stops pricing in the present; it prices in continued compounding.

The second-quarter report was the fuel. Revenue rose 8.8 percent to $673.3 million. Adjusted diluted EPS jumped 41.9 percent to $6.06, a solid beat against the roughly $5.60 the Street expected, and management raised full-year guidance to $25.00 to $25.75. The engine is VITAS, the hospice arm: net patient revenue up 11.9 percent to $443.3 million, average daily census up 6.1 percent, admissions up 9 percent, and adjusted EBITDA excluding the Medicare cap up 20.6 percent to $80.6 million.

But part of that headline growth came from a line that shrank rather than grew. Hospice providers bill Medicare under a per-patient cap, and each year they accrue a reserve against visits they may exceed it. In the prior-year quarter, Chemed recorded a $16.4 million Medicare Cap limitation, mostly tied to a Florida disruption. In this year's quarter, the charge collapsed to $0.5 million. That is roughly $16 million of year-over-year relief — about a dollar a share after tax, or close to half of the $1.79 of adjusted-EPS growth the company reported.

To be clear about what this is and is not: the Medicare Cap swing is an estimate, not a fraud. The prior year over-reserved against Florida; this year the program resolved and released it. The mechanics are disclosed and entirely legal. The reason it matters is the same reason any one-off comparator matters — it flatters the beat's quality. Call the quarter a strong beat flattered by a gift that cannot repeat. The lasting part of the story is whether VITAS's census growth carries the rest, which is exactly what the raised guidance banks on.

The second business is pulling the other way

The other half of Chemed is the part of the story still working to justify the price, not against it. Roto-Rooter grew revenue only 3.3 percent to $229.9 million, and its adjusted EBITDA was flat at $48.5 million, with the margin down 77 basis points. Management attributes the squeeze to roughly $3.1 million of extra internet marketing: free leads are down 13 percent while paid leads have risen to 59 percent of the mix, a structurally more expensive way to grow. It has answered by buying two franchises for $20.6 million and a South Texas territory in June, spending its way into growth while the organic channels get costlier.

Here is the shareholder invoice. It is not the $541,000. The guy who sold is irrelevant to what the business is worth; the 13,000 shares he kept would have been equally irrelevant if he had sold them all. The invoiced item is the four-month, 30 percent run that has pushed a Medicare-funded hospice operator to roughly 25 times trailing earnings, under the assumption the engine keeps beating. A cap reserve that swung $16 million in the company's favor shows how much slack is already being pulled out of that assumption, and Roto-Rooter shows the part of the business not cooperating.

The useful habit to take from a headline like this is to check the direction of the company's own money before reading anything into an individual officer's rounding error — and then to look inside the quarter, not the Form 4, for what changed. Chemed's buybacks and guidance point one way; the $16 million cap swing and a flat second business point to the margin of error in a 25-times price. The next document worth waiting for is not the next insider sale. It is the next quarter's Medicare Cap reserve and Roto-Rooter's margin, which will say whether the compounding the market is paying for is real or partly borrowed from a reserve.